ClinicalTrials.gg
CompletedNCT02704533Updated Feb 1, 2019

Sequential Optimization of Dose and Schedule of PfSPZ Vaccine

A Phase 1 interventional study of PfSPZ Vaccine and PfSPZ Challenge (NF54) in Malaria, sponsored by Sanaria Inc.. Completed at 1 site in Germany. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-02-01.

Sponsored by Sanaria Inc. · Phase 1, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 13 studies testing PfSPZ Challenge in Malaria — 1 open to participants now, 1 under way, none of them phase 3. PfSPZ Challenge · Malaria.

Enrollment
4th of 13
45 · median 30
Started
2016
the only one that year
Phase 1
11 of 13
none open now
Registered
9th of 13
by date
Lead sponsor
10 of 13
Sanaria Inc.

Among the 13 studies testing PfSPZ Challenge in Malaria, this one is the 4th largest by enrollment, is the only one that started in 2016, is one of 11 in phase 1, and was the 9th registered.

Malaria

1,185 studies on the registry are indexed under Malaria; 80 are open to participants now.

Browse Malaria studies →

Open to participants now

1 of the 13 studies testing PfSPZ Challenge in Malaria is open now. Recruiting first, the newest first:

About PfSPZ Challenge

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 52 Malaria studies recruiting now, 15 (29%) set no upper age limit and 34 (65%) stop at 75 or younger; 38 take children under 18; 32 take healthy volunteers.

This study: 18 Years to 45 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies testing PfSPZ Challenge in Malaria, or all of them as a file.
02

Study summary

MAVACHE is a sequential dose and schedule optimization trial of intravenous immunization with PfSPZ Vaccine in 18 to 54 malaria-naïve, healthy adult volunteers receiving 9x10\^5, 1.35x10\^6, or 2.7x10\^6 PfSPZ per dose and a total dose between 2.7x10\^6 and 8.1x10\^6 PfSPZ followed by CHMI with 3,200 fully infectious PfSPZ (PfSPZ Challenge).

PfSPZ Challenge (7G8) to assess vaccine efficacy, safety, tolerability and infectivity of ascending PfSPZ doses will be assessed in healthy, malaria-naïve volunteers.

Read the detailed description

The study is to take place at Institut für Tropenmedizin, Eberhard Karls Universität Tübingen, Tübingen Germany.

The study has two phases: 1) dose optimization, and 2) regimen verification. In the first phase groups A, B1, B2, C1, C2 and C3 will be vaccinated sequentially in a pre-specified order, followed by homologous CHMI with 3,200 PfSPZ Challenge (NF54) three weeks after last vaccine injection.

Dose optimization phase A: 9x10\^5 PfSPZ on Days 0, 7 and 28 (n = 6) B1: 1.35x10\^6 PfSPZ on Days 0 and 7 (n = 6) B2: 1.35x10\^6 PfSPZ on Days 0, 7, and 28 (n = 6) C1: 2.7x10\^6 PfSPZ on Day 0 (n = 6) C2: 2.7x10\^6 PfSPZ on Day 0 and 7 (n = 6) C3: 2.7x10\^6 PfSPZ on Days 0, 7 and 28 (n = 6)

In parallel to CHMI with PfSPZ Challenge (NF54) during the optimization phase, a total of nine volunteers will receive either 800, 1,600 or 3,200 PfSPZ Challenge (7G8) (PfSPZ Challenge (7G8) dose finding) to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) in malaria-naïve healthy adult volunteers.

PfSPZ Challenge (7G8) dose finding/infection D1: 800 PfSPZ (n = 3) D2: 1,600 PfSPZ (n = 3) D3: 3,200 PfSPZ (n = 3)

Subsequently, the shortest efficacious regimen (V1) and a three-dose regimen (Day 0, 7 and 28) of the highest safe dose (V2) will be selected and verified against placebo (normal saline (NS)). Groups V1 and V2 will be vaccinated at approximately the same time and undergo repeat CHMI three and eight weeks after the last immunization. Volunteers will either receive PfSPZ Vaccine or NS as placebo. Allocation will be random and double blind. Repeat CHMI will be done with PfSPZ Challenge (NF54) and PfSPZ Challenge (7G8), given in a randomized sequence. All immunizations are given by direct venous inoculation (DVI).

Regimen verification phase V1: Shortest efficacious regimen (n = 12) against placebo (n = 6) V2: Maximum regimen (n = 12) against placebo (n = 6) P1: Placebo for V1 group (n=6) P2 Placebo for V2 group (n=6)

03

Conditions studied

  • Malaria

Keywords

  • Plasmodium falciparum
  • PfSPZ Vaccine
  • PfSPZ Challenge (NF54)
  • PfSPZ Challenge (7G8)
  • CHMI
04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adults aged 18 to 45 years
  • Able and willing (in the Investigator's opinion) to comply with all study requirements
  • Willing to allow the investigators to discuss the volunteer's medical history with their general practitioner ('Hausarzt' in German) if required
  • Residence in Tübingen or surroundings for the period of the trial
  • Women only: Must agree to practice continuous effective for the duration of the study (a method which results in a failure rate less than 1% per year)
  • Agreement to refrain from blood donation during the course of the study and after the end of their involvement in the study according to the local and national blood banking eligibility criteria (currently there is a four year restriction in Germany)
  • Written to receive PfSPZ products:
  • Optimization phase: PfSPZ Vaccine for immunization and PfSPZ Challenge (NF54) for CHMI
  • PfSPZ Challenge (7G8) dose finding: PfSPZ Challenge (7G8) for CHMI
  • Verification phase: PfSPZ Vaccine for immunization, PfSPZ Challenge (NF54) and PfSPZ Challenge (7G8) for CHMI
  • Reachable (24/7) by mobile phone during the immunization and CHMI period
  • Willingness to take a curative antimalarial regimen following CHMI
  • Agreement to stay overnight for observation during the period of intensive follow-up post-challenge if required
  • Answer all questions on the informed consent quiz correctly
  • A \<35

Exclusion criteria

Exclusion Criteria:

  • History of P. falciparum malaria
  • Planned travel to malaria endemic areas before end of CHMI (28 days after CHMI)
  • Use of systemic antibiotics with known antimalarial activity within 30 days of study enrollment (e.g. trimethoprim-sulfamethoxazole, doxycycline, tetracycline, clindamycin, erythromycin, fluoroquinolones, or azithromycin)
  • Receipt of an product in the 30 days preceding enrollment, or planned receipt during the study period
  • Prior receipt of a malaria vaccine
  • Immunization with more than three other vaccines within the past four weeks
  • infection
  • Any confirmed or suspected or immunodeficient state, asplenia, recurrent, severe infections and chronic (more than 14 days) immunosuppressant medication within the past 6 months (inhaled and topical are allowed)
  • Use of immunoglobulins or blood products within 3 months prior to enrolment
  • Known or suspected hemolytic disease or presence of hemoglobinopathies
  • Pregnancy, lactation or intention to become pregnant during the study
  • to the use of the following antimalarial medications: atovaquoneproguanil, artemether-lumefantrine or mefloquine
  • History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)
  • History of serious psychiatric condition that may affect participation in the study (including but not restricted to organic, including symptomatic, mental disorders [ICD-10 code: F00-F09], schizophrenia, schizotypal and delusional disorders [F20-F29], mood (affective) disorders [F30-F39], mental retardation [F70-F79], Disorders of psychological development [F80-F89] or any other psychiatric condition that required hospitalization or psychiatric treatment over an extended period).
  • Any other serious chronic illness requiring hospital specialist supervision
  • Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 60 g (men) or 40 g (women) per day or a carbohydrate deficient transferrin (CDT) level ≥2.5%
  • Suspected or known injecting drug abuse in the 5 years preceding enrollment
  • Positive for surface antigen (HBs-antigen)
  • Seropositive for virus (antibodies to HCV)
  • Falling in moderate risk or higher categories for fatal or non-fatal cardiovascular event within 5 years (>10%) determined by non-invasive criteria for cardiac risk
  • Abnormal on screening: pathologic Q wave and significant ST-T wave changes, left ventricular hypertrophy, arrhythmias, left bundle branch block, secondary or tertiary A-V heart block
  • A /QTcB interval >450 ms
  • Volunteers unable to be closely followed for social, geographic or psychological reasons
  • Any clinically significant abnormal finding on biochemistry or hematology blood tests, urine analysis or clinical examination
  • History of seizure (except isolated and uncomplicated febrile convulsion at childhood)
  • Any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
45 participants (actual)

Study arms

  • Experimental
    Optimization Phase - Group A

    n=6; three times 9x10\^5 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group A will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine. If \>75% efficacious, the treatment will be simplified to two times 1.35x10\^6 PfSPZ Vaccine on Days 0 and 7 (Group B1). If \<75% efficacious, the treatment will be increased to three times 1.35x10\^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group B2)

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (NF54)

  • Experimental
    Optimization Phase - Group B1

    n=6; two times 1.35x10\^6 PfSPZ Vaccine on Days 0 and 7 by DVI. Group B1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine. If \>75% efficacious, the treatment will be simplified to one injection 2.7x10\^6 PfSPZ Vaccine (Group C1). If \<75% efficacious, the treatment will be increased to two times 2.7x10\^6 PfSPZ Vaccine on Days 0 and 7 (Group C2).

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (NF54)

  • Experimental
    Optimization Phase - Group B2

    n=6; three times 1.35x10\^6 PfSPZ Vaccine on Days 0, 7 and 28 by DVI. Group B2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after the last dose of vaccine. If \>75% efficacious, the treatment will be simplified to two times 2.7x10\^6 PfSPZ Vaccine on Days 0 and 7 (Group C2). If \<75% efficacious, the treatment will be increased to three times 2.7x10\^6 PfSPZ Vaccine on Days 0, 7 and 28 (Group C3).

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (NF54)

  • Experimental
    Optimization Phase - Group C1

    n=6; one time 2.7x10\^6 PfSPZ Vaccine by DVI. Group C1 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination. If Group C1 gets vaccinated, study will proceed to verification phase after completion.

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (NF54)

  • Experimental
    Optimization Phase - Group C2

    n=6; two times 2.7x10\^6 PfSPZ Vaccine by DVI. Group C2 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination. If Group C2 gets vaccinated, study will proceed to verification phase after completion.

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (NF54)

  • Experimental
    Optimization Phase - Group C3

    n=6; three times 2.7x10\^6 PfSPZ Vaccine by DVI. Group C3 will undergo homologous CHMI with 3,200 PfSPZ Challenge (NF54), 3 weeks after vaccination. In case C3 shows \<75% efficacy, verification phase will not be done.

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (NF54)

  • Experimental
    PfSPZ Challenge (7G8) dose finding - Group D1

    n=3, one dose of 800 PfSPZ Challenge (7G8) by DVI. This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment.

    Biological: PfSPZ Challenge (7G8)

  • Experimental
    PfSPZ Challenge (7G8) dose finding - Group D2

    n=3, one dose of 1,600 PfSPZ Challenge (7G8) by DVI. This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment.

    Biological: PfSPZ Challenge (7G8)

  • Experimental
    PfSPZ Challenge (7G8) dose finding - Group D3

    n=3, one dose of 3,200 PfSPZ Challenge (7G8) by DVI. This is a dose finding study to assess safety, tolerability and infectivity of PfSPZ Challenge (7G8) administered DVI. CHMI with PfSPZ Challenge (7G8) will be done approximately at the same time as homologous CHMI to assess efficacy of immunization with PfSPZ Vaccine in the dose optimization phase. All volunteers receiving CHMI will be monitored by thick blood smear microscopy and qPCR until Day 28 or antimalarial treatment.

    Biological: PfSPZ Challenge (7G8)

  • Experimental
    Verification Phase - Group V1

    n=12; optimal regimen from phase 1 - shortest, well tolerated safe schedule that provides \>75% protection (5/6) against homologous CHMI (V1). Optimal \& maximum regimens will be compared in this phase. The maximum regimen is a 3-dose regimen (Day 0, 7, 28) with highest well-tolerated PfSPZ Vaccine dose/injection (V2). Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart. CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered in one of 2 sequences (NF54-7G8 or 7G8-NF54). Allocation to the 2 sequences will be double blind, random, at a 1:1 ratio and nested within the intervention groups (V1 and V2 PfSPZ Vaccine and placebo (P1 and P2)). CHMI will be done at a dose of 3,200 PfSPZ unless the dose escalation study of PfSPZ Challenge (7G8) indicates that a different dose would be preferable for 7G8.

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (NF54) · Biological: PfSPZ Challenge (7G8)

  • Experimental
    Verification Phase - Group V2

    n=12; maximum regimen from the phase 1 - 3-dose regimen (Day 0, 7 and 28) with highest well-tolerated PfSPZ Vaccine dose per injection (V2). Optimal \& maximum regimens will be compared in this phase. The optimal regimen (shortest, well tolerated and safe schedule) that provides \>75% protection (5/6) against homologous CHMI (V1). In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10\^6 PfSPZ). Group V2/P2 will not be immunized. Efficacy will be determined by repeat CHMI 3 and 8 weeks after last immunization. Inoculation of 2 CHMIs will be done about 35 days (5 weeks) apart. CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1.

    Biological: PfSPZ Vaccine · Biological: PfSPZ Challenge (NF54) · Biological: PfSPZ Challenge (7G8)

  • Placebo comparator
    Verification Phase - Group P1

    n=6; normal saline as placebo. This group will follow the regimen selected for Group V1. Efficacy of the vaccination regimen will be determined by CHMI which will be done by repeat CHMI three and eight weeks after the last immunization. Inoculation of the two CHMIs will be done approximately 35 days (5 weeks) apart. CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1.

    Biological: PfSPZ Challenge (NF54) · Biological: PfSPZ Challenge (7G8) · Other: Normal saline

  • Placebo comparator
    Verification Phase - Group P2

    n=6; NS as placebo. This group will follow the regimen selected for Group V2. In case that shortest efficacious regimen during phase 1 is C3, 12 volunteers will be vaccinated and 6 volunteers will receive NS during this phase. In this case optimal regimen equals maximum regimen (3 x 2.7x10\^6 PfSPZ). Group V2/P2 will not be immunized. Efficacy will be determined by repeat CHMI 3 and 8 weeks after the last immunization. Inoculation of the 2 CHMIs will be done about 35 days (5 weeks) apart. CHMI with PfSPZ Challenge (NF54) and CHMI with PfSPZ Challenge (7G8) will be administered as described in Group V1.

    Biological: PfSPZ Challenge (NF54) · Biological: PfSPZ Challenge (7G8) · Other: Normal saline

Interventions

  • BiologicalPfSPZ Vaccine

    Aseptic, purified, vialed, cryopreserved, radiation-attenuated, Plasmodium falciparum sporozoites, strain NF54

  • Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain NF54

  • BiologicalPfSPZ Challenge (7G8)

    Live, infectious, aseptic, purified, vialed, cryopreserved, Plasmodium falciparum sporozoites, strain 7G8

  • OtherNormal saline

    0.9% sodium chloride

06

What researchers measure

Primary outcomes

  1. Number or occurrence of at least possibly related Grade 3 AEs and serious adverse events (SAEs) for PfSPZ Vaccine

    Number or occurrence of at least possibly related Grade 3 AEs and SAEs from time of first administration of PfSPZ Vaccine to the end of the follow-up period.

    Time frame: Around 14 months (from day of first immunization through study completion)

  2. PfSPZ Challenge (7G8) dose finding - Number or occurrence of at least possibly related Grade 3 AEs and SAEs

    Number or occurrence of at least possibly related Grade 3 AEs and SAEs from time of first administration of PfSPZ Challenge (7G8) to the end of the follow-up period.

    Time frame: Around 140 days (from day of first PfSPZ Challenge (7G8) CHMI through end of follow-up)

Secondary outcomes

  1. Number of adverse events following immunization (AEFI) for PfSPZ Vaccine

    Number of adverse events following immunization (AEFI) from time of first administration of PfSPZ Vaccine to first administration of PfSPZ Challenge for CHMI consistent with a causal relationship.

    Time frame: About 7 weeks (from day of first vaccination until 3 weeks after last vaccination)

  2. Proportion of volunteers who become parasitemic will be recorded, detected by thick blood film microscopy or qPCR

    Thick blood film microscopy and quantitative polymerase chain reaction (qPCR) assays will be performed during CHMI follow-up. The proportion of volunteers who become parasitemic will be recorded, detected by thick blood film microscopy or qPCR, within 28 days following CHMI with 3,200 PfSPZ, given either as a single dose of 3,200 PfSPZ Challenge (NF54) (optimization phase) or as two subsequent injections of 3,200 PfSPZ Challenge (NF54) and PfSPZ Challenge (7G8), respectively in the verification phase.

    Time frame: Up to 4 weeks (from day of CHMI until 28 days)

  3. Proportion of volunteers who do not become parasitemic (protected) against homologous (NF54) and heterologous (7G8) CHMI, respectively.

    This endpoint can only be assessed during the verification phase of the trial.

    Time frame: About 28 days (from day of first CHMI till 28 days)

07

Study locations

1 site
  • Institute of Tropical Medicine, University of Tuebingen, Wilhelmstr. 27
    Tübingen, D-72074, Germany
08

References and documents

Publications

  • Mordmuller B, Sulyok Z, Sulyok M, Molnar Z, Lalremruata A, Calle CL, Bayon PG, Esen M, Gmeiner M, Held J, Heimann HL, Woldearegai TG, Ibanez J, Flugge J, Fendel R, Kreidenweiss A, Kc N, Murshedkar T, Chakravarty S, Riyahi P, Billingsley PF, Church LWP, Richie TL, Sim BKL, Hoffman SL, Kremsner PG. A PfSPZ vaccine immunization regimen equally protective against homologous and heterologous controlled human malaria infection. NPJ Vaccines. 2022 Aug 23;7(1):100. doi: 10.1038/s41541-022-00510-z. PubMed 35999221 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2016 to primary completion in Oct 2018, 25 months.

Of 29 industry-sponsored phase 1 interventional studies under Malaria, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 18. This study's 25 months is above that.

Counting every sponsor, half of 93 studies reached it within 13 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2016
First posted
Mar 10, 2016
StartActual
Aug 29, 2016
Primary completionActual
Oct 19, 2018
CompletionActual
Dec 2018
Last update
Feb 1, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 1, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02704533
Lead sponsor
Sanaria Inc.
Collaborators
Institute of Tropical Medicine, University of Tuebingen, German Federal Ministry of Education and Research, German Center for Infection Research
Responsible party
Sponsor
First posted
Mar 10, 2016
Start date
Aug 29, 2016
Primary completion
Oct 19, 2018
Completion
Dec 2018
Last update
Feb 1, 2019

Study contacts

Benjamin Mordmüller, MD
principal investigator · Institute of Tropical Medicine, University of Tuebingen, Wilhelmstr. 27, Germany

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PfSPZ Challenge

Start the discussion